Samar Khalil1, Tara Bardawil1, Mazen Kurban1,2, Ossama Abbas3. 1. Department of Dermatology, American University of Beirut Medical Center, Beirut, Lebanon. 2. Department of Biochemistry and Molecular Genetics, American University of Beirut, Beirut, Lebanon. 3. Department of Dermatology, American University of Beirut Medical Center, Beirut, Lebanon. oa09@aub.edu.lb.
Abstract
PURPOSE: Tissue-resident memory T (TRM) cells are a newly described subset of memory T cells. The best characterized TRM cells are CD8+ and express CD103 and CD69. These cells are non-recirculating and persist long term in tissues, providing immediate protection against invading pathogens. However, their inappropriate activation might contribute to the pathogenesis of autoimmune and inflammatory disorders. In the skin, these cells have been described in psoriasis, vitiligo, and melanoma among other diseases. METHODS: Literature review was done to highlight what is currently known on the phenotype and function of TRM cells and summarizes the available data describing their role in various cutaneous conditions. RESULTS: Resolved psoriatic skin and disease-naïve non-lesional skin contain a population of IL-17-producing TRM cells with shared receptor sequences that recognize common antigens and likely contribute to disease recurrence after cessation of therapy. In vitiligo, TRM cells produce perforin, granzyme B, and interferon-γ following stimulation by interleukin-15 and collaborate with recirculating memory T cells to maintain disease. In melanoma, increased accumulation of TRM cells was recently shown to correlate with improved survival in patients undergoing therapy with immune checkpoint inhibitors.
PURPOSE: Tissue-resident memory T (TRM) cells are a newly described subset of memory T cells. The best characterized TRM cells are CD8+ and express CD103 and CD69. These cells are non-recirculating and persist long term in tissues, providing immediate protection against invading pathogens. However, their inappropriate activation might contribute to the pathogenesis of autoimmune and inflammatory disorders. In the skin, these cells have been described in psoriasis, vitiligo, and melanoma among other diseases. METHODS: Literature review was done to highlight what is currently known on the phenotype and function of TRM cells and summarizes the available data describing their role in various cutaneous conditions. RESULTS: Resolved psoriatic skin and disease-naïve non-lesional skin contain a population of IL-17-producing TRM cells with shared receptor sequences that recognize common antigens and likely contribute to disease recurrence after cessation of therapy. In vitiligo, TRM cells produce perforin, granzyme B, and interferon-γ following stimulation by interleukin-15 and collaborate with recirculating memory T cells to maintain disease. In melanoma, increased accumulation of TRM cells was recently shown to correlate with improved survival in patients undergoing therapy with immune checkpoint inhibitors.
Entities:
Keywords:
Dermatitis; Fixed drug eruption; Melanoma; Psoriasis; Tissue-resident T cells
Authors: Anusha-Preethi Ganesan; James Clarke; Oliver Wood; Eva M Garrido-Martin; Serena J Chee; Toby Mellows; Daniela Samaniego-Castruita; Divya Singh; Grégory Seumois; Aiman Alzetani; Edwin Woo; Peter S Friedmann; Emma V King; Gareth J Thomas; Tilman Sanchez-Elsner; Pandurangan Vijayanand; Christian H Ottensmeier Journal: Nat Immunol Date: 2017-06-19 Impact factor: 25.606
Authors: Youdong Pan; Tian Tian; Chang Ook Park; Serena Y Lofftus; Shenglin Mei; Xing Liu; Chi Luo; John T O'Malley; Ahmed Gehad; Jessica E Teague; Sherrie J Divito; Robert Fuhlbrigge; Pere Puigserver; James G Krueger; Gökhan S Hotamisligil; Rachael A Clark; Thomas S Kupper Journal: Nature Date: 2017-02-20 Impact factor: 49.962
Authors: Jillian M Richmond; James P Strassner; Mehdi Rashighi; Priti Agarwal; Madhuri Garg; Kingsley I Essien; Lila S Pell; John E Harris Journal: J Invest Dermatol Date: 2018-11-10 Impact factor: 8.551
Authors: Timothy Murray; Silvia A Fuertes Marraco; Petra Baumgaertner; Natacha Bordry; Laurène Cagnon; Alena Donda; Pedro Romero; Grégory Verdeil; Daniel E Speiser Journal: Front Immunol Date: 2016-12-12 Impact factor: 7.561
Authors: Pamela C Rosato; Sathi Wijeyesinghe; J Michael Stolley; Christine E Nelson; Rachel L Davis; Luke S Manlove; Christopher A Pennell; Bruce R Blazar; Clark C Chen; Melissa A Geller; Vaiva Vezys; David Masopust Journal: Nat Commun Date: 2019-02-04 Impact factor: 14.919
Authors: J A Seidel; M Vukmanovic-Stejic; B Muller-Durovic; N Patel; J Fuentes-Duculan; S M Henson; J G Krueger; M H A Rustin; F O Nestle; K E Lacy; A N Akbar Journal: Clin Exp Immunol Date: 2018-09-12 Impact factor: 4.330
Authors: J Justin Milner; Clara Toma; Bingfei Yu; Kai Zhang; Kyla Omilusik; Anthony T Phan; Dapeng Wang; Adam J Getzler; Toan Nguyen; Shane Crotty; Wei Wang; Matthew E Pipkin; Ananda W Goldrath Journal: Nature Date: 2017-12-06 Impact factor: 49.962
Authors: Emrullah Korkmaz; Stephen C Balmert; Tina L Sumpter; Cara Donahue Carey; Geza Erdos; Louis D Falo Journal: Adv Drug Deliv Rev Date: 2021-02-02 Impact factor: 17.873